Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23014IDB-L5

Select Item

Empower your strategies with our Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2024 report and make more profitable business decisions.

Transitional cell carcinoma (TCC), also known asurothelial cell carcinoma, is a type of cancer that primarily affects the transitional epithelial cells lining the urinary tract, including the bladder, ureters, and renal pelvis. It is the most common form of bladder cancer. TCC arises when these cells undergo malignant changes, often due to exposure to carcinogens like tobacco or certain industrial chemicals. Symptoms may include blood in urine, frequent urination, and painful urination. Diagnosis involves imaging, cystoscopy, and biopsy. Treatment options depend on the stage and may include surgery, chemotherapy, radiation, immunotherapy, and targeted therapies. Early detection and treatment are essential for improving outcomes in patients with TCC.

The Transitional Cell Carcinoma (Urothelial Cell Carcinoma) drugs in development market research report provide comprehensive information on the therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Key Targets
· Programmed Cell Death Protein 1; Programmed Cell Death 1 Ligand 1; Fibroblast Growth Factor Receptor 2; Fibroblast Growth Factor Receptor 3; Receptor Tyrosine Protein Kinase ERBB 2; Tubulin ; Fibroblast Growth Factor Receptor 1; Vascular Endothelial Growth Factor Receptor 2; Tumor Necrosis Factor Receptor Superfamily Member 9; and Cytotoxic T Lymphocyte Protein 4
Key Mechanisms of Action
· Programmed Cell Death Protein 1 Antagonist; Programmed Cell Death 1 Ligand 1 Inhibitor; Fibroblast Growth Factor Receptor 2 Inhibitor; Fibroblast Growth Factor Receptor 3 Inhibitor; Fibroblast Growth Factor Receptor 1 Inhibitor; Tubulin Inhibitor; Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Fibroblast Growth Factor Receptor 4 Inhibitor; and Cytotoxic T Lymphocyte Protein 4 Antagonist
Key Routes of Administration
· Intravenous; Oral; Subcutaneous; Intravenous Drip; Parenteral; Intratumor; Intravesical; Intraperitoneal; Intramuscular; and Intralesional
Key Molecule Types
· Monoclonal Antibody; Small Molecule; Monoclonal Antibody Conjugated; Fusion Protein; Biologic; Oncolytic Virus; Subunit Vaccine; Recombinant Protein; mRNA Vaccine; and Gene-Modified Cell Therapy
Major Companies
· Bristol-Myers Squibb Co; Incyte Corp; Jiangsu Hengrui Medicine Co Ltd; F. Hoffmann-La Roche Ltd; CSPC Pharmaceutical Group Ltd; Abbisko Therapeutics Co Ltd; AstraZeneca Plc; Xencor Inc; RemeGen Co Ltd; and Sanofi

Scope

  • Therapeutics in Development: Covering 164 molecules, with 162 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Transitional Cell Carcinoma (Urothelial Cell Carcinoma) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Transitional Cell Carcinoma (Urothelial Cell Carcinoma) treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

3D Medicines Inc
Abbisko Therapeutics Co Ltd
AbbVie Inc
Acrotech Biopharma LLC
Adaptimmune Therapeutics Plc
Adcentrx Therapeutics Inc
AIM ImmunoTech Inc
Akamis Bio Ltd
Akeso Inc
Alligator Bioscience AB
Alphamab Oncology
Amgen Inc
Anhui Anke Biotechnology (Group) Co Ltd
Anwita Biosciences Inc
Aravive Inc
Astellas Pharma Inc
AstraZeneca Plc
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Bicycle Therapeutics Plc
Bio-Path Holdings Inc
BioNTech SE
Biotheus Inc
Bioviz Technologies Pvt Ltd
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Catalym GmbH
Centrymed Pharmaceutical Inc
CicloMed LLC
Clinigen Ltd
CSPC Pharmaceutical Group Ltd
Daiichi Sankyo Co Ltd
Dyadic International Inc
Eikon Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Ella Therapeutics Ltd
Ellipses Pharma Ltd
Evopoint Bioscience Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
GenFleet Therapeutics (Shanghai) Inc
Genome & Co
Gritstone Bio Inc
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
HCW Biologics Inc
Heilongjiang ZBD Pharmaceutical Co Ltd
Hengrui Yuanzheng Biotechnology Co Ltd
Hibercell Inc
HitGen Inc
Icahn School of Medicine at Mount Sinai
Immunocore Holdings Plc
Immunorock Co Ltd
Incyte Corp
Inhibrx Inc
IO Biotech Inc
iOmx Therapeutics AG
Ipsen SA
Istari Oncology Inc
IVY Pharma Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kinnate Biopharma Inc
KLUS Pharma Inc
Lee's Pharmaceutical Holdings Ltd
Lindis Biotech GmbH
Lipac Oncology LLC
Luye Pharma Group Ltd
Mabwell Shanghai Bioscience Co Ltd
Mayo Clinic
Merck & Co Inc
Millennium Pharmaceuticals Inc
Minghui Pharmaceutical (Shanghai) Co Ltd
Moderna Inc
MorphoSys AG
Mural Oncology Inc
Nanology LLC
NextPoint Therapeutics Inc
OncoQuest Inc
Orion Corp
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Prestige BioPharma Ltd
PRISM Pharma Co.
Ltd.
Promontory Therapeutics Inc
Pyxis Oncology Inc
RAPT Therapeutics Inc
RemeGen Co Ltd
Replimune Ltd
Sanofi
Scholar Rock Inc
Shandong Boan Biotechnology Co Ltd
Shandong Buchang Pharmaceutical Co Ltd
Shandong New Time Pharmaceutical Co Ltd
Shandong Taize Huikang Biomedical Co Ltd
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Biosciences Co Ltd
Shanghai Lingda Biopharmaceutical Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shionogi & Co Ltd
Simcere Pharmaceutical Group Ltd
Simcha Therapeutics Inc
Sinovant Sciences HK Ltd
Sunho (China) Biopharmaceutical Co Ltd
Sustained Therapeutics Inc
SynOx Therapeutics Ltd
Systimmune Inc
UCB SA
Vaxiion Therapeutics Inc
Vaximm AG
WindMIL Therapeutics Inc
Xencor Inc
Zhejiang Teruisi Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Transitional Cell Carcinoma (Urothelial Cell Carcinoma) reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2024 in real time.

  • Access a live Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more